In vitro-in vivo availability of metformin hydrochloride-PLGA nanoparticles in diabetic rats in a periodontal disease experimental model

Context Metformin is an important oral anti-hyperglycemic used in diabetes. Polylactic-co-glycolic acid (PLGA) has been widely used due to its reliability in controlling the release of drugs. Objective This study evaluates the in vitro-in vivo availability of metformin hydrochloride-loaded polylacti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aline de Sousa Barbosa Freitas Pereira, Maria Laura de Souza Lima, Arnobio Antonio da Silva-Junior, Emanuell dos Santos Silva, Raimundo Fernandes de Araújo Júnior, Agnes Andrade Martins, Jovelina Samara Ferreira Alves, Artur de Santana Oliveira, Leandro De Santis Ferreira, Emily Cintia Tossi de Araújo Costa, Gerlane Coelho Bernardo Guerra, Caroline Addison Carvalho Xavier de Medeiros, Gerly A. C. Brito, Renata Ferreira de Carvalho Leitao, Aurigena Antunes de Araújo
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	polylactic-co-glycolic acid bioavailability diabetes Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/7d4d72e176694e5aa3a792b23b8a3c96
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7d4d72e176694e5aa3a792b23b8a3c96
record_format	dspace
spelling	oai:doaj.org-article:7d4d72e176694e5aa3a792b23b8a3c962021-11-26T11:19:47ZIn vitro-in vivo availability of metformin hydrochloride-PLGA nanoparticles in diabetic rats in a periodontal disease experimental model1388-02091744-511610.1080/13880209.2021.2002369https://doaj.org/article/7d4d72e176694e5aa3a792b23b8a3c962021-01-01T00:00:00Zhttp://dx.doi.org/10.1080/13880209.2021.2002369https://doaj.org/toc/1388-0209https://doaj.org/toc/1744-5116Context Metformin is an important oral anti-hyperglycemic used in diabetes. Polylactic-co-glycolic acid (PLGA) has been widely used due to its reliability in controlling the release of drugs. Objective This study evaluates the in vitro-in vivo availability of metformin hydrochloride-loaded polylactic-co-glycolic acid. Material and methods In vitro metformin release (Met-free or PLGA + Met-12.5 mg/mL per 360 min) was evaluated using static Franz vertical diffusion cells. The in vivo study was performed with two control groups (validation bioanalytical method) and two experimental groups of diabetic male Wistar rats treated with PLGA + Met 10 mg/kg or Met 100 mg/kg by oral gavage. Diabetes was induced by streptozotocin (40 mg/kg) through the penile vein. Blood samples were collected 0.5, 1, 4, 7, 10, 12, 18, 24, 36, 48 and 72 h and analysed by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Results PLGA + Met 10 mg/kg was released in the in vitro assay suggesting a parabolic diffusion kinetic model (K −0.0619−0.5h) with a 100% release profile in 10 h by controlled diffusion. The in vivo assay showed the apparent volume of distribution Vz/F (PLGA + Met 10 mg/kg, 40971.8 mL/kg vs. Met 100 mg/kg, 2174.58 mL/kg) and mean residence time MRTinf (PLGA + Met 10 mg/kg, 37.66 h vs. Met 100 mg/kg, 3.34 h). Discussion and Conclusions The formulation modifies pharmacokinetics parameters such as apparent distribution volume and mean residence time. The PLGA + Met 10 mg/kg had a slower elimination rate compared to Met 100 mg/kg in diabetic rats in a periodontal disease experimental model.Aline de Sousa Barbosa Freitas PereiraMaria Laura de Souza LimaArnobio Antonio da Silva-JuniorEmanuell dos Santos SilvaRaimundo Fernandes de Araújo JúniorAgnes Andrade MartinsJovelina Samara Ferreira AlvesArtur de Santana OliveiraLeandro De Santis FerreiraEmily Cintia Tossi de Araújo CostaGerlane Coelho Bernardo GuerraCaroline Addison Carvalho Xavier de MedeirosGerly A. C. BritoRenata Ferreira de Carvalho LeitaoAurigena Antunes de AraújoTaylor & Francis Grouparticlepolylactic-co-glycolic acidbioavailabilitydiabetesTherapeutics. PharmacologyRM1-950ENPharmaceutical Biology, Vol 59, Iss 1, Pp 1576-1584 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	polylactic-co-glycolic acid bioavailability diabetes Therapeutics. Pharmacology RM1-950
spellingShingle	polylactic-co-glycolic acid bioavailability diabetes Therapeutics. Pharmacology RM1-950 Aline de Sousa Barbosa Freitas Pereira Maria Laura de Souza Lima Arnobio Antonio da Silva-Junior Emanuell dos Santos Silva Raimundo Fernandes de Araújo Júnior Agnes Andrade Martins Jovelina Samara Ferreira Alves Artur de Santana Oliveira Leandro De Santis Ferreira Emily Cintia Tossi de Araújo Costa Gerlane Coelho Bernardo Guerra Caroline Addison Carvalho Xavier de Medeiros Gerly A. C. Brito Renata Ferreira de Carvalho Leitao Aurigena Antunes de Araújo In vitro-in vivo availability of metformin hydrochloride-PLGA nanoparticles in diabetic rats in a periodontal disease experimental model
description	Context Metformin is an important oral anti-hyperglycemic used in diabetes. Polylactic-co-glycolic acid (PLGA) has been widely used due to its reliability in controlling the release of drugs. Objective This study evaluates the in vitro-in vivo availability of metformin hydrochloride-loaded polylactic-co-glycolic acid. Material and methods In vitro metformin release (Met-free or PLGA + Met-12.5 mg/mL per 360 min) was evaluated using static Franz vertical diffusion cells. The in vivo study was performed with two control groups (validation bioanalytical method) and two experimental groups of diabetic male Wistar rats treated with PLGA + Met 10 mg/kg or Met 100 mg/kg by oral gavage. Diabetes was induced by streptozotocin (40 mg/kg) through the penile vein. Blood samples were collected 0.5, 1, 4, 7, 10, 12, 18, 24, 36, 48 and 72 h and analysed by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Results PLGA + Met 10 mg/kg was released in the in vitro assay suggesting a parabolic diffusion kinetic model (K −0.0619−0.5h) with a 100% release profile in 10 h by controlled diffusion. The in vivo assay showed the apparent volume of distribution Vz/F (PLGA + Met 10 mg/kg, 40971.8 mL/kg vs. Met 100 mg/kg, 2174.58 mL/kg) and mean residence time MRTinf (PLGA + Met 10 mg/kg, 37.66 h vs. Met 100 mg/kg, 3.34 h). Discussion and Conclusions The formulation modifies pharmacokinetics parameters such as apparent distribution volume and mean residence time. The PLGA + Met 10 mg/kg had a slower elimination rate compared to Met 100 mg/kg in diabetic rats in a periodontal disease experimental model.
format	article
author	Aline de Sousa Barbosa Freitas Pereira Maria Laura de Souza Lima Arnobio Antonio da Silva-Junior Emanuell dos Santos Silva Raimundo Fernandes de Araújo Júnior Agnes Andrade Martins Jovelina Samara Ferreira Alves Artur de Santana Oliveira Leandro De Santis Ferreira Emily Cintia Tossi de Araújo Costa Gerlane Coelho Bernardo Guerra Caroline Addison Carvalho Xavier de Medeiros Gerly A. C. Brito Renata Ferreira de Carvalho Leitao Aurigena Antunes de Araújo
author_facet	Aline de Sousa Barbosa Freitas Pereira Maria Laura de Souza Lima Arnobio Antonio da Silva-Junior Emanuell dos Santos Silva Raimundo Fernandes de Araújo Júnior Agnes Andrade Martins Jovelina Samara Ferreira Alves Artur de Santana Oliveira Leandro De Santis Ferreira Emily Cintia Tossi de Araújo Costa Gerlane Coelho Bernardo Guerra Caroline Addison Carvalho Xavier de Medeiros Gerly A. C. Brito Renata Ferreira de Carvalho Leitao Aurigena Antunes de Araújo
author_sort	Aline de Sousa Barbosa Freitas Pereira
title	In vitro-in vivo availability of metformin hydrochloride-PLGA nanoparticles in diabetic rats in a periodontal disease experimental model
title_short	In vitro-in vivo availability of metformin hydrochloride-PLGA nanoparticles in diabetic rats in a periodontal disease experimental model
title_full	In vitro-in vivo availability of metformin hydrochloride-PLGA nanoparticles in diabetic rats in a periodontal disease experimental model
title_fullStr	In vitro-in vivo availability of metformin hydrochloride-PLGA nanoparticles in diabetic rats in a periodontal disease experimental model
title_full_unstemmed	In vitro-in vivo availability of metformin hydrochloride-PLGA nanoparticles in diabetic rats in a periodontal disease experimental model
title_sort	in vitro-in vivo availability of metformin hydrochloride-plga nanoparticles in diabetic rats in a periodontal disease experimental model
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/7d4d72e176694e5aa3a792b23b8a3c96
work_keys_str_mv	AT alinedesousabarbosafreitaspereira invitroinvivoavailabilityofmetforminhydrochlorideplgananoparticlesindiabeticratsinaperiodontaldiseaseexperimentalmodel AT marialauradesouzalima invitroinvivoavailabilityofmetforminhydrochlorideplgananoparticlesindiabeticratsinaperiodontaldiseaseexperimentalmodel AT arnobioantoniodasilvajunior invitroinvivoavailabilityofmetforminhydrochlorideplgananoparticlesindiabeticratsinaperiodontaldiseaseexperimentalmodel AT emanuelldossantossilva invitroinvivoavailabilityofmetforminhydrochlorideplgananoparticlesindiabeticratsinaperiodontaldiseaseexperimentalmodel AT raimundofernandesdearaujojunior invitroinvivoavailabilityofmetforminhydrochlorideplgananoparticlesindiabeticratsinaperiodontaldiseaseexperimentalmodel AT agnesandrademartins invitroinvivoavailabilityofmetforminhydrochlorideplgananoparticlesindiabeticratsinaperiodontaldiseaseexperimentalmodel AT jovelinasamaraferreiraalves invitroinvivoavailabilityofmetforminhydrochlorideplgananoparticlesindiabeticratsinaperiodontaldiseaseexperimentalmodel AT arturdesantanaoliveira invitroinvivoavailabilityofmetforminhydrochlorideplgananoparticlesindiabeticratsinaperiodontaldiseaseexperimentalmodel AT leandrodesantisferreira invitroinvivoavailabilityofmetforminhydrochlorideplgananoparticlesindiabeticratsinaperiodontaldiseaseexperimentalmodel AT emilycintiatossidearaujocosta invitroinvivoavailabilityofmetforminhydrochlorideplgananoparticlesindiabeticratsinaperiodontaldiseaseexperimentalmodel AT gerlanecoelhobernardoguerra invitroinvivoavailabilityofmetforminhydrochlorideplgananoparticlesindiabeticratsinaperiodontaldiseaseexperimentalmodel AT carolineaddisoncarvalhoxavierdemedeiros invitroinvivoavailabilityofmetforminhydrochlorideplgananoparticlesindiabeticratsinaperiodontaldiseaseexperimentalmodel AT gerlyacbrito invitroinvivoavailabilityofmetforminhydrochlorideplgananoparticlesindiabeticratsinaperiodontaldiseaseexperimentalmodel AT renataferreiradecarvalholeitao invitroinvivoavailabilityofmetforminhydrochlorideplgananoparticlesindiabeticratsinaperiodontaldiseaseexperimentalmodel AT aurigenaantunesdearaujo invitroinvivoavailabilityofmetforminhydrochlorideplgananoparticlesindiabeticratsinaperiodontaldiseaseexperimentalmodel
_version_	1718409543956824064

In vitro-in vivo availability of metformin hydrochloride-PLGA nanoparticles in diabetic rats in a periodontal disease experimental model

Ejemplares similares